Bevacizumab

Where the papers sit

47 papers from the last 6 months study bevacizumab directly · updated from PubMed 12 Oct 2026

• Immunotherapy Sequencing in HCC

  First-line atezolizumab plus bevacizumab is being integrated into broader HCC treatment pathways that include response assessment, transplantation, TACE and second-line therapy. RECIST 1.1 and mRECIST comparisons, DCP levels and response-pattern analyses seek to refine prediction beyond overall survival. Durvalumab plus tremelimumab provides a key alternative, with later lenvatinib or immunotherapy choices remaining unsettled. The direction is toward biomarker-guided sequencing rather than a single preferred regimen.

  12 papers · 25.5%

• Atezolizumab in Liver Cancer

  Atezolizumab plus bevacizumab is being assessed as first-line treatment for unresectable hepatocellular carcinoma through real-world survival, safety and economic analyses. Poor skeletal muscle and fat measures, AFP status and early LMR dynamics recur as possible outcome markers. Finotonlimab plus bevacizumab is emerging as another cost-effectiveness comparator against sorafenib. The evidence is moving from trial adoption toward patient selection and health-system value.

  10 papers · 21.3%

• Therapeutic Antibody Characterization

  Therapeutic antibody testing is moving toward rapid, orthogonal measurement of concentration, molecular size, charge and oligomerization. UPLC-MS/MS quantifies bevacizumab in plasma, while hyperspectral micro-Raman imaging offers label-free serum characterization. Single-protein oscillators and hydrodynamic models aim to assess size and charge without conventional fractionation. The open question is how these faster assays will complement established chromatography in quality control and clinical pharmacology.

  4 papers · 8.5%

• Others — Bevacizumab Outcomes and Toxicity

  Hypertension, proteinuria, thrombotic microangiopathy and pulmonary vascular changes recur as clinically important toxicities across bevacizumab-treated cancers. Other studies use imaging, prognostic signatures and machine learning to predict progression or treatment benefit in glioma, colorectal cancer and renal cancer. Combination strategies span atezolizumab, ipilimumab, chemotherapy, erlotinib and trifluridine/tipiracil, with results varying by tumour and molecular context. The cluster has no single disease focus or unified direction.

  16 papers · 34%

• Others — Vascular Injury and Cancer Therapy

  Radiation-related edema, necrosis and plexopathy are recurring treatment targets, while ENO1 lactylation links metabolic reprogramming to ovarian bevacizumab resistance. Other work examines inflammatory pyroptosis in sepsis-induced kidney injury and bevacizumab-based induction followed by atezolizumab. Dosing studies seek better control of radiation necrosis across tumour types. The cluster has no single disease focus or consistent therapeutic direction.

  5 papers · 10.6%